Compugen Stock Price, News & Analysis

Compugen Ltd. (CGEN) presented new research on PVRIG, emphasizing its role as a distinct immune checkpoint that may enhance T-cell expansion. Findings suggest that PVRIG clusters with early memory T cell markers, indicating its potential when used with TIGIT and PD-1 inhibitors for tumors unresponsive to current therapies. The study highlights PVRIG's expression in T cells and its potential to trigger immune responses. The presentation was made at the SITC 2021 seminar.

Compugen Ltd. (Nasdaq: CGEN) presented updated data from its Phase 1 study of COM701, a first-in-class anti-PVRIG antibody, at ASCO 2021. The combination of COM701 with Opdivo® demonstrated a 66.7% disease control rate in 15 evaluable patients, with a notable complete response in a patient with anal squamous cell carcinoma lasting 22 months. The monotherapy showed a 47.2% disease control rate across 36 patients, with preliminary biomarker data indicating enhanced immune response. These findings highlight the potential for COM701 in difficult-to-treat cancers, including ongoing evaluation in immunotherapy-resistant populations.

Compugen Ltd. (Nasdaq: CGEN) announced participation in a virtual event to discuss data from its Phase 1 clinical trial of COM701, an innovative antibody targeting PVRIG. The findings will be presented on June 7, 2021, at the ASCO 2021 Annual Meeting. A fireside chat hosted by Truist Securities analyst Asthika Goonewardene is scheduled for June 8, 2021, featuring key executives from Compugen. The company is focused on developing cancer immunotherapy treatments, including the ongoing studies of COM701 and COM902.

Compugen Ltd. (CGEN) reported Q1 2021 financial results with a net loss of $9.9 million or $0.12 per share, an increase from a $7.1 million loss in Q1 2020. R&D expenses rose to $7.3 million, up from $4.7 million, driven by drug manufacturing and clinical activities. The company has $119.4 million in cash reserves. Upcoming milestones include data readouts for COM701 in various studies and collaboration with Bristol Myers Squibb for a Phase 1b study. Compugen aims to lead in the DNAM axis space with promising clinical data for PVRIG and TIGIT assets.

Compugen Ltd. (NASDAQ: CGEN) announced that Eran Ophir, Ph.D., Vice President of Research and Drug Discovery, will participate in the Society for Immunotherapy of Cancer's online seminar on June 29, 2021. The seminar focuses on 'The TIGIT Pathway' and is part of a series addressing key questions in cancer immunotherapy. Co-chairs include industry experts, and an interactive Q&A session will follow. Compugen, based in Israel, is developing innovative cancer therapies, including its lead anti-PVRIG antibody, COM701, currently in Phase 1 trials.

Compugen Ltd. (CGEN) announced an expansion of its research collaboration with Johns Hopkins University on a novel myeloid target discovered through its predictive computational platform. Initial preclinical studies indicate significant tumor growth inhibition upon genetic deletion of this target, potentially serving as a myeloid immunomodulator. The collaboration aims to further investigate the biological function of this target, enhancing Compugen's immuno-oncology pipeline. The CEO emphasizes the importance of early-stage programs for the company's growth and development in cancer therapies.

Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company, will release its first quarter 2021 financial results on May 13, 2021, before U.S. markets open. A conference call will be held at 8:30 AM ET to discuss the results and provide an update. Investors can join via telephone or through a live webcast on Compugen's website. The company is advancing its lead candidate, COM701, an anti-PVRIG antibody for solid tumors, which is currently in a Phase 1 clinical study, alongside COM902, targeting TIGIT.

Compugen Ltd. (CGEN) announced an oral presentation at the ASCO 2021 Annual Meeting, scheduled for June 7, 2021. The presentation will provide updates on the ongoing Phase 1 trial of COM701, a therapeutic antibody targeting PVRIG for advanced solid tumors. Noteworthy details include the title of the oral presentation and its focus on the safety, tolerability, and preliminary antitumor activity of COM701, evaluated with or without nivolumab. The abstract will be accessible on May 19, 2021, on ASCO.org.

Compugen Ltd. (CGEN) announced the publication of preclinical data on COM902, a novel anti-TIGIT therapeutic antibody, in Cancer Immunology, Immunotherapy. Key findings show that COM902 enhances anti-tumor immune responses by blocking TIGIT, which is expressed in various solid tumors. It demonstrates no T cell depletion activity, potentially preserving immune function. The ongoing Phase 1 trial for COM902 is expected to report initial results in Q4 2021, with further studies combining it with other therapies planned for H2 2021.